About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in New York State | 13,041 Studies Near You | Clareo Health

Clinical Trials LocationsNew York State

Clinical Trials in New York State

Discover 13,041 clinical trials near New York. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 9921-9940 of 13,041 trials

COMPLETEDPhase 264 miles

A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma

NCT02014142

Determine efficacy of the latanoprost punctal plug. Effect of configuration of L-PPDS placement on efficacy will also be examined.

Ocular HypertensionOpen-Angle Glaucoma

Mati Therapeutics Inc.86 participantsStarted Dec 2013

Chandler, Arizona, United States • Phoenix, Arizona, United States • Torrance, California, United States +15 more locations

COMPLETEDPhase 366 miles

Perennial Allergic Rhinitis Study In Pediatric Subjects

NCT00108914

The purpose of this study is to determine if the investigational drug is effective and safe in children with perennial allergic rhinitis.

Rhinitis, Allergic, Perennial

GlaxoSmithKline558 participantsStarted Feb 2005

Costa Mesa, California, United States • Cudahy, California, United States • Long Beach, California, United States +63 more locations

Find Trials by Condition in New York State

Breast Cancerin New York State Lung Cancerin New York State Prostate Cancerin New York State Colorectal Cancerin New York State Melanomain New York State Leukemiain New York State Lymphomain New York State Pancreatic Cancerin New York State Ovarian Cancerin New York State Brain Cancerin New York State

Data from ClinicalTrials.govTerms

COMPLETEDPhase 368 miles

Lamotrigine Extended-Release In Elderly Patients With Epilepsy

NCT00516139

This study is being conducted to determine the safety and tolerability of lamotrigine (LTG) in elderly patients with epilepsy. This study will be carried out using an extended-release formulation of lamotrigine (LTG-XR) that will allow once-a-day dosing.

GlaxoSmithKline122 participantsStarted Aug 2007

Birmingham, Alabama, United States • Gilbert, Arizona, United States • Litchfield Park, Arizona, United States +60 more locations

COMPLETEDPhase 369 miles

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's

NCT00363727

This study evaluates how effective a new formulation of a marketed drug is in increasing the time to onset of dyskinesia (abnormal twisting, writhing movements) in patients with Parkinson's Disease who have been taking levodopa for less than 2 years.

Parkinson's DiseaseParkinson DiseaseDyskinesias

GlaxoSmithKline209 participantsStarted Dec 2003

Anniston, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +66 more locations

COMPLETEDPhase 286 miles

Pediatric Epilepsy Study in Subjects 1-24 Months

NCT00044278

This study will evaluate the long-term safety of LAMICTAL(lamotrigine)in subjects with partial seizures previously enrolled in protocol LAM20006 and in subjects 1-24 months of age who have never received LAMICTAL(LAMICTAL-naive). For LAMICTAL-naive subjects, LAMICTAL will be added to the subject's current epilepsy medications.

GlaxoSmithKline197 participantsStarted Sep 2000

Mobile, Alabama, United States • Tucson, Arizona, United States • Jonesboro, Arkansas, United States +67 more locations

COMPLETEDPhase 397 miles

BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis

NCT00095173

The primary purpose of the clinical research study is to assess the safety of treating children and juvenile subjects with BMS-188667 (Abatacept). In addition, the study will assess the effectiveness of BMS-188667 in reducing disease activity of Juvenile Rheumatoid Arthritis (JRA) or Juvenile Idiopathic Arthritis (JIA) as measured by the time to occurrence of disease flare.

Juvenile Rheumatoid Arthritis

Bristol-Myers Squibb214 participantsStarted Dec 2003

Omaha, Nebraska, United States • Livingston, New Jersey, United States • New Hyde Park, New York, United States +33 more locations

COMPLETEDPhase 399 miles

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02107196

Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea. This trial aims at the evaluation of the efficacy and safety of oral ibodutant 10 mg once daily as compared to placebo in women with IBS-D over a 12-week treatment period.

Irritable Bowel Syndrome With Diarrhea

Menarini Group535 participantsStarted Mar 2014

Huntsville, Alabama, United States • Sherwood, Arizona, United States • Little Rock, Arkansas, United States +124 more locations

COMPLETEDPhase 499 miles

Study Of Asthma In Patients Of African Descent

NCT00102765

This study will last up to 62 weeks. You will visit the clinic up to 17 times. Certain clinic visits will include physical examination, medical history review and lung function tests. The purpose of this study is to see if one asthma drug (fluticasone propionate/salmeterol) is better in reducing the number of asthma exacerbations compared with another drug (fluticasone propionate alone)

GlaxoSmithKline479 participantsStarted Nov 2004

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +72 more locations

COMPLETEDPhase 2107 miles

Use of Activated Recombinant FVII in Spinal Surgery

NCT00102037

This trial is conducted in the United States of America (USA). The purpose of this clinical research trial is to understand how safe and effective Recombinant Activated FVII is for reducing bleeding and blood transfusions in patients undergoing spinal fusion surgery.

Acquired Bleeding DisorderSpinal Fusion

Novo Nordisk A/S50 participantsStarted Jul 2004

Sacramento, California, United States • San Francisco, California, United States • Washington D.C., District of Columbia, United States +11 more locations

COMPLETED126 miles

GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus

NCT01950637

This study is conducted Asia, Europe and North America. The aim of this study is to describe insulin therapy adherence and the burden of non-adherence on patient functioning, well-being and diabetes management.

DiabetesDiabetes Mellitus, Type 2

Novo Nordisk A/S4,000 participantsStarted Jan 2012

Princeton, New Jersey, United States • Mississauga, Canada • Copenhagen S, Denmark +3 more locations

COMPLETEDPhase 3127 miles

A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301

NCT01017146

The purpose of this study is to assess safety and efficacy of a new foam formulation of tazarotene in subjects with acne vulgaris.

Stiefel, a GSK Company744 participantsStarted Oct 2009

Denver, Colorado, United States • Miami Beach, Florida, United States • Indianapolis, Indiana, United States +19 more locations

COMPLETEDPhase 2153 miles

Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke

NCT00240643

This study will allow determination of the pharmacokinetic and pharmacodynamics of SB424323 in a relevant population. The data from this study will be used along with other data to aid in choosing the most appropriate dose for the later phase study.

Fibrillation, AtrialAtrial Fibrillation

GlaxoSmithKline640 participantsStarted Nov 2005

Mobile, Alabama, United States • Troy, Michigan, United States • Akron, Ohio, United States +113 more locations

COMPLETEDPhase 4191 miles

Chronic Obstructive Pulmonary Disease Endpoints Study

NCT00358358

This study will last for approximately 14 weeks and will involve 5 visits. The study is being carried out to look at different ways of measuring the effect of drug treatment on COPD. COPD is a respiratory disease which can affect your breathing and daily life. Symptoms of COPD can include breathlessness, cough, and wheeze. COPD varies enormously from patient to patient. The effects of drug treatment are usually measured by conducting lung function tests (breathing tests) using a machine called a spirometer but this does not always provide a complete picture of how well your COPD is responding. In this study we therefore want to look at new and more sensitive ways of measuring COPD. The results of this research will help in the assessment of new drugs for COPD in the future.

Pulmonary Disease, Chronic Obstructive

GlaxoSmithKline163 participantsStarted Mar 2006

Absecon, New Jersey, United States • Charleston, South Carolina, United States • Greenville, South Carolina, United States +8 more locations

COMPLETEDPhase 2206 miles

A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion

NCT01222117

The primary purpose of this Phase 2 study is to optimize Plasmin delivery by comparing different delivery regimens in patients with peripheral arterial occlusion. The study includes a blinded plasminogen activator treatment group and a blinded plasminogen activator placebo group. The study will also assess safety and tolerability of Plasmin at 150 and 250 mg doses.

Acute Peripheral Arterial Occlusion

Grifols Therapeutics LLC174 participantsStarted Dec 2010

Buffalo, New York, United States • Cleveland, Ohio, United States • Genk, Limburg, Belgium +36 more locations

COMPLETEDPhase 3212 miles

A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification

NCT02100475

This trial is conducted globally. The aim of the trial is to compare sequential addition of insulin aspart versus further dose increase with insulin degludec/liraglutide in subjects with type 2 diabetes mellitus, previously treated with insulin degludec/liraglutide and metformin and in need of further intensification. This is an extension to trial NN9068-3952, NCT01952145 (DUAL™ V).

DiabetesDiabetes Mellitus, Type 2

Novo Nordisk A/S31 participantsStarted Apr 2014

Fresno, California, United States • Fort Lauderdale, Florida, United States • Gurnee, Illinois, United States +57 more locations

COMPLETEDPhase 3345 miles

Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

NCT01668797

The purpose of this study is to evaluate the efficacy of brexpiprazole compared with placebo as maintenance treatment in adults with schizophrenia.

Acute Schizophrenia

Otsuka Pharmaceutical Development & Commercialization, Inc.524 participantsStarted Oct 2012

Anaheim, California, United States • Cerritos, California, United States • Garden Grove, California, United States +46 more locations

COMPLETEDPhase 2/31051 miles

Arimoclomol in Sporadic Inclusion Body Myositis

NCT00769860

Inclusion body myositis (IBM) is the most common progressive and debilitating muscle disease beginning in persons over 50 years of age. This study will assess the safety and tolerability of Arimoclomol in IBM as compared to placebo over 4 months of treatment.

Inclusion Body Myositis

Richard Barohn, MD24 participantsStarted Sep 2008

Kansas City, Kansas, United States • London, United Kingdom

COMPLETED1421 miles

Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies

NCT01287988

The primary objective of this study is to assess visual function in up to 44 patients who have previously participated in either of the placebo controlled, ocriplasmin Phase III studies (TG-MV-006 or TG-MV-007).

Symptomatic Vitreomacular Adhesion

ThromboGenics24 participantsStarted May 2011

Houston, Texas, United States • Leuven, Belgium

COMPLETEDPhase 21930 miles

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

NCT00426803

This trial is conducted in North America, Europe, Asia and Oceania. The purpose of this study is to evaluate safety and efficacy of Recombinant Factor VIIa in patients with acute intracerebral bleeding.

Acquired Bleeding DisorderIntracerebral Haemorrhage

Novo Nordisk A/S400 participantsStarted Aug 2002

Melbourne, Australia • Graz, Austria • Antwerp, Belgium +12 more locations

COMPLETED2113 miles

Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication

NCT00869908

This study is conducted in Africa, Asia, South America and Europe. The aim of this observational study is to document the experience with the study insulins when used in routine clinical practice. After the physician's decision to start insulin treatment using NovoMix® 30, Levemir® or NovoRapid® (alone or combined), type 2 diabetics will be eligible to be included in this study at the physician's discretion

DiabetesDiabetes Mellitus, Type 2

Novo Nordisk A/S66,726 participantsStarted Nov 2008

Algiers, Algeria • Prov. de Buenos Aires, Argentina • Dhaka, Bangladesh +19 more locations

PreviousPage 497 of 653Next

Diabetes

in New York State

Heart Diseasein New York State